louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03227822: Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease
Official title: Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease; a Pilot Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Peripheral Arterial Disease
Lead sponsor: Catharina Ziekenhuis Eindhoven
Sponsor class: OTHER
First posted: 2017-07-24
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Since the length of lesion seems to be negatively associated with stent patency due to restenosis, it is thought that the efficacy of treatment in patients with multiple (\> 1) short (focal; \> 1 and \< 5 cm) SFA lesions can be improved by spot stenting as compared to the use of one long stent. This study proposes to evaluate the endovascular treatment for patients with SFA lesions by comparing two strategies for patients with extensive occlusive SFA disease; 1) short spot (SS) stenting or 2) long lesion (LL) stenting.


Eligibility criteria: Inclusion Criteria:

* PAOD (ABI \<0.90 and/or a decline of \>0.15 after exercise test), Rutherford category 2, 3 or 4
* Multiple (\>1) short (focal; \>1 and \< 5 cm) significant stenoses (≥ 50%) and/or occlusions in the superficial femoral artery
* Eligible for endovascular treatment via short spot stenting and via long lesion stenting according to international guidelines
* Unilateral occlusive disease
* Age ≥ 18

Exclusion Criteria:

* Patients with PAOD Rutherford category 5 and 6
* Impaired inflow due to significant lesions in the arteries proximal to the SFA intended to treat
* Bilateral lesions with treatment indication
* Contra-indication for anticoagulant therapy
* Renal insufficiency (MDRD \< 50 ml/min)
* Life expectancy \< 6 months
* Known contrast allergy
* Pregnancy
* Unable to complete a questionnaire in the home language

Primary outcomes:
measure: absence of binary restenosis (≥ 50% re-obstruction) of the target lesion without interval clinically driven reintervention
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02174822: A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
Official title: A Phase 1, Single-center, Open-label, Sequential Drug Interaction Study Between AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [DM]/Quinidine Sulfate [Q]) and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Drug-drug Interaction
Keywords: Drug-drug interaction
Pharmacokinetics
Healthy Volunteers
deuterated dextromethorphan
deuterated dextromethorphan with quinidine
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor class: INDUSTRY
First posted: 2014-06-26
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: To assess steady state pharmacokinetics (PK), safety and tolerability between AVP-786 (deuterated \[d6\] dextromethorphan hydrobromide \[DM\]/quinidine sulfate \[Q\]) and paroxetine and between AVP-786 and duloxetine.


Eligibility criteria: Inclusion Criteria:

* Healthy adult males and females
* 18 - 50 years of age
* BMI 18 - 30 kg/m2

Exclusion Criteria:

* History or presence of significant disease
* History of substance abuse and/or alcohol abuse with the past 3 years
* Use of tobacco-containing or nicotine-containing products within 6 months
* Use of any prescription or the over-the-counter medications within 14 days

Primary outcomes:
measure: Change in plasma concentrations of paroxetine after combined dosing with AVP-786 paroxetine in healthy subjects
timeFrame: 20 days
measure: Change in plasma concentration of AVP-786 (parent and metabolites) after dosing in combination with paroxetine.
timeFrame: 20 days
measure: Change in plasma concentration of duloxetine after combined dosing with AVP-786
timeFrame: 13 days
measure: Change in plasma concentration of AVP-786 after combined dosing with duloxetine.
timeFrame: 13 days
Secondary outcomes:
measure: Incidence of adverse events (AEs) for AVP-786 and paroxetine
timeFrame: 20 days
measure: Incidence of adverse events (AEs) for AVP-786 and duloxetine
timeFrame: 13 days
Other outcomes:
Locations:
city: Melbourne
country: Australia
facility: Nucleus Network
state: Victoria
Study officials:
affiliation: Nucleus Network
name: Jason Lickliter, MBBS PhD FRACP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00435422: Neuroaxial Blokade and Blood Pressure
Official title: Neuroaxial Blokade and the Effect of Fluid Optimization
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hypovolemia
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2007-02-15
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The effect of individualized fluid optimization during neuroaxial blockade has not been evaluated. The investigators evaluated if if Stroke decrease 15 min after activation of neuroaxial blockade and whether SV could be optimized to pre activation values.

Detailed description: The purpose of this study is to evaluate SV maximization with aid of the LiDCO system which is a minimal invasive technique only requiring a venous and arterial line. We thereby attempt to cover the specific individual fluid deficit induced by neuroaxial blockade.

Eligibility criteria: Inclusion Criteria:

* Neuroaxial blockade (thoracic)

Exclusion Criteria:

* Weight below 40 kg
* Lithium therapy
* Type I diabetes or type II requiring insulin

Primary outcomes:
measure: Stroke volume
timeFrame: 15 min after blockade
Secondary outcomes:
measure: Brain oxygenation, cardiac output, TPR, NIRS, BP
timeFrame: 15 min after blockade
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Rigshospitalet
Study officials:
affiliation: Section of surgical pathophysiology
name: Morten Bundgaard-Nielsen, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: unafiliated
name: Morten Bundgaard-Nielsen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01623622: Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke
Official title: A Phase 2 Study of HC-58 in Patients With Severe Upper Limb Hemiplegia After Stroke
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Severe Upper Limb Hemiplegia
Lead sponsor: Asahi Kasei Pharma Corporation
Sponsor class: INDUSTRY
First posted: 2012-06-20
Enrollment: 270
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to investigate the efficacy and safety of HC-58 in patients with severe upper limb hemiplegia following stroke.


Eligibility criteria: Inclusion Criteria:

* Patients with severe upper limb hemiplegia after stroke
* Within 28 days after stroke at enrollment

Exclusion Criteria:

* Patients with sensory loss between shoulder and hand on paralyzed side
* Patients with pain between shoulder and hand on paralysed side which affects medical rehabilitation

Primary outcomes:
measure: Onset of shoulder hand syndrome
timeFrame: 12 weeks
measure: Change from Baseline in the modified Barthel index (MBI) and MBI efficiency
timeFrame: 12 weeks
measure: Change from Baseline in the Fugl-Meyer Assessment (FMA) (upper limb) and FMA efficiency
timeFrame: 12 weeks
Secondary outcomes:
measure: Pain score by numeric rating scale
timeFrame: 12 weeks
measure: Swelling asymmetry between hands
timeFrame: 12 weeks
measure: Discolouration of the skin of the hand
timeFrame: 12 weeks
measure: Difference in skin temperature between hands
timeFrame: 12 weeks
measure: Decreased range of motion
timeFrame: 12 weeks
measure: Radiographic finding of bone
timeFrame: 12 weeks
measure: Bone metabolic marker
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Hamamatsu
country: Japan
state: Shizuoka
city: Fukui
country: Japan
city: Kumamoto, Kumamoto
country: Japan
Study officials:
affiliation: Asahi Kasei Pharma Corporation Clinical Development Center
name: Toshiya Umeda
role: STUDY_DIRECTOR
References:
Clinical trial NCT02473822: ACL Reconstruction With the TLS Technique
Official title: ACL Reconstruction With the TLS Technique (Tape Locking Screw) and Return to Sport: Serial 5-year Independent Designers
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Joint Trauma
Keywords: anterior cruciate ligament
Tape Locking Screw
LCA
joint trauma
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2015-06-17
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients undergoing care of knee instability in chronic laxity of anterior cruciate ligament by ligament according to TLS technique.

Brief summary: This is a non-interventional study to retrospectively validate the technical use TLS (Tape Locking Screw) in the anterior cruciate ligament. The investigators goal is to test the validity of the technique and its positive influence on the resumption of sporting activities in relation to the existing literature.


Eligibility criteria: Inclusion Criteria:

* Patients over 18 years
* Patients operated in the service in 2014 to care for end-stage knee osteoarthritis by implantation of a total knee prosthesis.

Exclusion Criteria:

* Patients under 18 years

Primary outcomes:
measure: Resumption of sporting activities
timeFrame: every 3 months over a period of one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital, Strasbourg, France
name: Jean-Yves JENNY, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00414739: Testing of Innocuousness of Benzalkonium Chloride on the Eye Concerning Possible Growth of Langerhans Cells
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Eye Diseases
Keywords: growth of dendritic cells
prevention
Lead sponsor: University of Rostock
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2006-12-22
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study analysis the influence of benzalkonium chloride on the density of antigen presenting Langerhans cells. This is achieved in a double blind randomized study using in-vivo confocal microscopy to identify and quantify Langerhans cells of the human cornea in its central and peripheral part. This study design is based on observations with raised Langerhans cell density after the application of benzalkonium chloride containing eye drops in glaucoma patients.


Eligibility criteria: Inclusion Criteria:

* healthy probands

Exclusion Criteria:

* eye diseases
* pregnancy and lactation period
* drug dependency

Primary outcomes:
measure: Possible raised Langerhans cell density in the corneal epithelium
Secondary outcomes:
Other outcomes:
Locations:
city: Rostock
country: Germany
facility: University of Rostock, Eye Department
Study officials:
affiliation: University of Rostock, Eye Department
name: Rudolf F. Guthoff, Prof. Dr.
role: STUDY_CHAIR
References:
citation: De Saint Jean M, Brignole F, Bringuier AF, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999 Mar;40(3):619-30.
citation: Becquet F, Goldschild M, Moldovan MS, Ettaiche M, Gastaud P, Baudouin C. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998 Apr;17(4):419-25. doi: 10.1080/02713689808951223.
citation: Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001 Sep-Oct;18(5):205-15. doi: 10.1007/BF02853166.
citation: Eckard A, Stave J, Guthoff RF. In vivo investigations of the corneal epithelium with the confocal Rostock Laser Scanning Microscope (RLSM). Cornea. 2006 Feb;25(2):127-31. doi: 10.1097/01.ico.0000170694.90455.f7.
citation: Zhivov A, Stachs O, Kraak R, Stave J, Guthoff RF. In vivo confocal microscopy of the ocular surface. Ocul Surf. 2006 Apr;4(2):81-93. doi: 10.1016/s1542-0124(12)70030-7.
citation: Zhivov A, Stave J, Vollmar B, Guthoff R. In vivo confocal microscopic evaluation of Langerhans cell density and distribution in the normal human corneal epithelium. Graefes Arch Clin Exp Ophthalmol. 2005 Oct;243(10):1056-61. doi: 10.1007/s00417-004-1075-8. Epub 2005 Oct 20.
Clinical trial NCT00004339: Study of Tetrathiomolybdate in Patients With Wilson Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Wilson Disease
Keywords: Wilson disease
inborn errors of metabolism
rare disease
Lead sponsor: National Center for Research Resources (NCRR)
Sponsor class: NIH
Collaborators: name: University of Michigan
First posted: 1999-10-19
Enrollment: 90
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: OBJECTIVES:

Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically.

Detailed description: PROTOCOL OUTLINE: This a double blind, randomized study. Patients are randomized into one of two treatment arms.

Arm I: Patients receive tetrathiomolybdate (TM) 3 times a day with meals and 3 times a day between meals for 8 weeks in the absence of neurologic deterioration or unacceptable toxicity.

Arm II: Patients receive trientine therapy for 8 weeks in the absence of neurologic deterioration and unacceptable toxicity.

Additional therapy (off study): Patients in the TM group may receive maintenance zinc, while those in the trientine group may continue on trientine or switch to zinc.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

* Wilson disease presenting with neurologic or psychiatric symptoms
* No concurrent seizure activity
* No white matter lesions on brain magnetic resonance imaging

--Prior/Concurrent Therapy--

* No more than 2 weeks of prior therapy
* No penicillamine or trientine for longer than 2 weeks

--Patient Characteristics--

* Hepatic: No severe hepatic failure
* Other: No psychiatric or medical contraindication to protocol therapy
* Not pregnant

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: George J. Brewer
role: STUDY_CHAIR
References:
citation: Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin K, Fink JK, Aisen A. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol. 1994 Jun;51(6):545-54. doi: 10.1001/archneur.1994.00540180023009.
citation: Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 1996 Oct;53(10):1017-25. doi: 10.1001/archneur.1996.00550100103019.
citation: Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006 Apr;63(4):521-7. doi: 10.1001/archneur.63.4.521.
Clinical trial NCT02515539: Early Feasibility Study of the CardiAQ™ TMVI System (Transfemoral and Transapical DS)
Official title: Early Feasibility Study of the CardiAQ™ Transcatheter Mitral Valve Implantation (TMVI) System (Transfemoral and Transapical Delivery Systems)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Mitral Insufficiency
Heart Valve Disease
Cardiovascular Disease
Heart Disease
Keywords: Transcatheter Mitral Valve Replacement
Mitral Regurgitation
Mitral Insufficiency
Transapical
Transfemoral
Lead sponsor: Edwards Lifesciences
Sponsor class: INDUSTRY
First posted: 2015-08-04
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to generate early US feasibility data of the CardiAQ™ Transcatheter Mitral Valve Implant System.

The study will enroll patients with moderate to severe mitral valve regurgitation who are considered high risk for mortality and morbidity from conventional open-heart surgery.

Detailed description: Early feasibility study - multi-center, prospective, single-arm, and non-randomized study without concurrent or historical controls.

The primary objective of the study is to generate early feasibility data for the CardiAQ™ Transcatheter Mitral Valve Implant System with the Transfemoral and Transapical Delivery Systems for the treatment of moderate to severe mitral valve regurgitation in patients who are considered high risk for mortality and morbidity from conventional open-heart surgery.

The secondary objectives of the study are to evaluate the long-term safety of the device and the effects of the device on performance, functional, quality of life parameters, and technical, device, procedural, and individual patient successes.

The study is to be performed at a maximum of 5 investigational sites in the US.

Eligibility criteria: Key Inclusion Criteria:

* NYHA Classification ≥ III
* Left Ventricular Ejection Fraction ≥ 30%
* Mitral Regurgitation ≥ Grade 3+
* Subject meets anatomical and eligibility criteria for the investigational device

Exclusion Criteria:

* See Protocol

Primary outcomes:
measure: Composite Major Adverse Event Rate
timeFrame: 30-Day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Pennsylvania
name: Wilson Szeto, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Pennsylvania
name: Howard Herrmann, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Cedars-Sinai Medical Center
name: Saibal Kar, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Cedars-Sinai Medical Center
name: Alfredo Trento, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06468839: The Impact of Addiction Management Model on Digital Addiction and Psychological Resilience in Second School Students
Official title: The Impact of Addiction Management Model on Digital Addiction and Psychological Resilience in Second School Students
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Technology Addiction, Psychological Resilience, Risky Technology Use in Adolescent
Keywords: adolescent health, technology addiction, internet addiction health education, psychological resilience, emotional freedom tecnique.
Lead sponsor: Ankara University
Sponsor class: OTHER
First posted: 2024-06-21
Enrollment: 80
Sex: ALL
Minimum age (years): 11
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Digital addiction has become a prevalent concern among adolescents, particularly middle school students. This study aims to develop and evaluate an addiction management model for 6th-grade students at risk of digital addiction. The model will combine standardized psychological resilience training with emotional freedom techniques to address both the behavioral and emotional aspects of digital addiction.


Eligibility criteria: Inclusion Criteria:

High risk of digital addiction as a result of the screening, Secondary school 6th grade students, Volunteering of the student and parent to participate in the research, The student must be able to speak, read and understand Turkish, The student does not have an auditory or mental disability that would affect his/her participation in the research.

Exclusion Criteria:

-

Primary outcomes:
measure: Assessing Digital Addiction Risk Level
timeFrame: 1-3 month
Secondary outcomes:
Other outcomes:
Locations:
city: Çankaya
country: Turkey
facility: Senem Çelik Yavuz
state: Ankara
Study officials:
affiliation: Ankara University
name: Ayfer TEZEL, professor
role: STUDY_CHAIR
References:
Clinical trial NCT04979039: Heart Rate Variability to Predict Hypotension Following Spinal Anesthesia in Cesarean Delivery
Official title: Heart Rate Variability Monitoring to Predict Hypotension Following Spinal Anesthesia for Cesarean Delivery: Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cesarean Section
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2021-07-27
Enrollment: 50
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult pregnant women scheduled for cesarean section under spinal anesthesia

Brief summary: Based on the patient's heart rate variability, the analgesia nociception index (ANI) measures the activity of the autonomic nervous system and the sympathetic/parasympathetic nervous system and expresses it as a numerical value through a specific algorithm. The investigators will analyze it and see if it has the ability to predict severe hypotension following spinal anesthesia.


Eligibility criteria: Inclusion Criteria:

* Adult pregnant women scheduled for cesarean section under spinal anesthesia

Exclusion Criteria:

* Emergency cesarean section
* When performing general anesthesia or epidural anesthesia
* Multiple pregnancies
* Surgery in which massive hemorrhage and massive blood transfusion are expected due to placenta previa
* Cardiac arrhythmias, congestive heart failure, ischemic heart disease, congenital heart anomalies
* Cranial nervous system disease
* Autonomic nervous system-related underlying diseases not related to pregnancy
* Fetal malformations
* Those who have an allergic skin reaction to adhesive substances such as bandages

Primary outcomes:
measure: The change of averaged value
timeFrame: 15 min, 10 min and 5 min before entering the operating room; every 5 min after entering the operating room
measure: The change of instantaneous value
timeFrame: 15 min, 10 min and 5 min before entering the operating room; every 5 min after entering the operating room
measure: Total dose of injected phenylephrine
timeFrame: During the anesthesia (from initiation of anesthesia until the end of anesthesia)
measure: Total dose of injected glycopyrrolate
timeFrame: During the anesthesia (from initiation of anesthesia until the end of anesthesia)
measure: The change of systolic blood pressure
timeFrame: Every 1 min after entering the operating room until finishing the operation
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi
Study officials:
References: